STOCKS TELEGRAPH

Tag: PPBT stock

  • Purple Biotech (PPBT) Stock Gains Pre-Hour Momentum

    Purple Biotech (PPBT) Stock Gains Pre-Hour Momentum

    In pre-market trading, Purple Biotech Ltd. (NASDAQ: PPBT) had a notable stock increase this morning, going up 57.08% to $5.27. The spike comes after PPBT revealed positive Phase 2 clinical research findings for CM24, its top cancer medication. Patients with pancreatic ductal adenocarcinoma (PDAC) were screened for this humanized monoclonal antibody, which targets CEACAM1.

    Phase 2 Study: A Milestone in PDAC Treatment

    The randomized Phase 2 study revealed CM24’s ability to deliver consistent improvements across all evaluated efficacy endpoints. Particularly noteworthy were the enhanced outcomes in patients with specific biomarkers such as CEACAM1 and other serum indicators. These results demonstrate how CM24 may have a major effect on cancers that express CEACAM1.

    These findings are encouraging to clinicians and researchers, especially when it comes to late-stage metastatic PDAC, when there are few available treatments. Refining patient selection based on biomarker profiles may also improve treatment results, according to the data.

    The Role of CEACAM1 and NETs

    A key insight from the study is the role of CEACAM1 and neutrophil extracellular traps (NETs) in determining the efficacy of CM24. Tumors with moderate levels of CEACAM1 and NET-related markers like MPO were most responsive, encompassing 80% of the Nal-IRI cohort. This suggests that tumors with low reliance on these markers or excessively high levels may not benefit as significantly from the treatment.

    Purple Biotech plans to further explore these dynamics in a forthcoming Phase 2b study. The trial will compare three arms: CM24 with a PD1 inhibitor, CM24 monotherapy, and standard-of-care (SoC) chemotherapy. The study aims to evaluate the necessity of PD1 blockade alongside CM24 and to target patients with elevated CEACAM1 and MPO levels.

    Expanding Horizons in Oncology

    These findings position CM24 as a versatile therapeutic candidate for multiple cancer types expressing CEACAM1. Purple Biotech’s approach of concentrating on patient groups that are biomarker-enriched may greatly improve the effectiveness of CM24. PPBT continues to be at the forefront of cutting-edge cancer therapies as it moves on to the next stage of clinical testing.

  • Purple Biotech Ltd. (PPBT) stock is moving high in the premarket – What’s up?

    Purple Biotech Ltd. (PPBT) stock is moving high in the premarket – What’s up?

    Purple Biotech Ltd. (PPBT) experienced an increase of 5.34% in the premarket despite any official news. However, the last trading session closed at $2.62.

    Appointment of Ori Hershkovitz – Latest News by PPBT

    On 6th January 2022, PPBT announced that Ori Hershkovitz has been appointed a member of the Board of directors. Over the course of his career, Mr. Hershkovitz has worked in a variety of capacities in life sciences investment funds. Moreover, he currently serves on the boards of private and public biotechnology firms. He was the Managing Partner and Chief Investment Officer of Nexthera Fund. It is a New York-based healthcare hedge fund with over $400 million in assets under management, from 2015 to 2019. Lastly, he was the Founding Partner and Head of Research at Sphera Fund in Tel-Aviv from 2006 to 2014, where he oversaw the management of over $700 million in assets.

    Now what?

    The company welcomes Ori to the Purple Biotech Board of Directors very happily. In addition, the company has spent a significant amount of time investing in and coaching early-stage life sciences startups. As PPBT continues to execute on the corporate growth plans, the company looks forward to leveraging its industry and financial knowledge.

    Appointment of Chief Business Officer by PPBT – What’s going on?

    On 9th December 2021, PPBT announced the appointment of Fabien Sebille as Chief Business Officer. Fabien’s extensive scientific background and substantial business development expertise are best for the job of Chief Business Officer. Furthermore, the company is happy to have him join the team, and the company anticipates Fabien leading the business growth efforts. Fabien’s expertise will be essential to the company strategy and objectives as they continue to advance the promising oncology-focused pipeline, led by CM24 and NT219, and search for future growth possibilities.

    Initiation of Part 2 of Phase 1/2 Clinical Trial – What’s new?

    On 6th December 2021, PPBT reported that the ongoing phase of the clinical trial meant to evaluate NT219 has been initiated. The progression of the ongoing Phase 1/2 clinical trial to Part 2 is an important achievement. The early signs of efficacy, as well as safety patterns, seen in Part 1 of the research, have encouraged them. Lastly, in the first half of 2022, the company anticipates the release of more preliminary effectiveness data from Part 1 of the study.